Skip to main content
Premium Trial:

Request an Annual Quote

Roche, GE to Develop Integrated Digital Diagnostics for Oncology, Critical Care Treatment

NEW YORK (360Dx) – Roche said today that it has entered a strategic, long-term partnership with GE Healthcare to jointly develop and comarket digital clinical decision support solutions.

The firm said that the partnership will focus first on developing products that accelerate and improve individualized treatment options for cancer and critical care patients.

Financial terms of the deal were not disclosed.

The partners will apply advanced analytics to in vivo data from GE's medical imaging and monitoring equipment and to in vitro data from Roche's biomarker, tissue pathology, genomics, and sequencing portfolio.

Roche Diagnostics CEO Roland Diggelmann said in a statement that the goal of the partnership is "to support clinicians and other relevant stakeholders for the benefit of patients by providing the right decision support at the right time and through comprehensive digital offerings."

The two companies are aiming to develop a digital platform that uses advanced analytics to provide workflow solutions and apps that support clinical decisions, Roche said, adding that this would enable "the seamless integration and analysis of in vivo and in vitro data, patient records, medical best practice, real time monitoring, and the latest research outcomes."

Clinicians will have "the comprehensive decision support" for providing the right treatment and quality of care for their patients, Roche said. Oncology care teams with multiple specialists would be able to review a comprehensive data dashboard, and collaborate and align on treatment decisions for cancer patients at each stage of their disease.

Roche also noted that in the critical care setting, data from patients' hospital monitoring equipment will be integrated with their biomarker, genomic, and sequencing data, helping physicians to identify, or even predict severe complications before they happen.

"This is the first time that two major players in healthcare have combined digital, in vivo and in vitro diagnostics to this degree," added GE Healthcare President and CEO Kieran Murphy.


The Scan

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.

Study Points to Synonymous Mutation Effects on E. Coli Enzyme Activity

Researchers in Nature Chemistry saw signs of enzyme activity shifts in the presence of synonymous mutations in a multiscale modeling analysis of three Escherichia coli genes.

Team Outlines Paternal Sample-Free Single-Gene Approach for Non-Invasive Prenatal Screening

With data for nearly 9,200 pregnant individuals, researchers in Genetics in Medicine demonstrate the feasibility of their carrier screening and reflex single-gene non-invasive prenatal screening approach.

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.